Agfa has published its Q3 figures, which show a slight drop in performance compared with last year’s Q3 results, but with a noticeable uptick for the Digital Print and Chemicals division.
Thus the Digital Print and Chemicals business saw revenues rise from €99 million to €110 million in Q3, and from €300 million to €313 million for the first nine months of this year. This includes 19 percent growth in digital printing solutions, 10 percent of which is down to ink sales as Agfa converts its Inca Onset customers from Fujifilm to Agfa inksets. The company also scored a number of installations from recent product launches, including the first Speedset 1060 packaging press.
The Chemicals side grew its Zirfon sales by 15 percent, which should realise further growth in the near future as a new production plant comes into play. In the meantime, Agfa picked up its first major customer in India.
The healthcare IT business reported a slight fall in revenues, from €60 million to €58 million for Q3, and from €180 million to €167 million for the first nine months. Agfa says that some of this is down to the market transitioning to cloud technology, noting that 45 percent of total Q3 order intake is cloud-related.
At the same time, the adjusted Earnings Before Interest, Taxes, Depreciation and Amortisation dropped from €8.5 million to €6.3 million, which represents a fall from 14 percent of revenue margin to 10.9 percent. Agfa attributes this to effects from its product mix, pointing out that it has secured several new Enterprise Imaging contracts.
However, the Radiology Solutions business experienced a steeper fall, from €103 million to €92 million for Q3 and from €309 million to €277 million for the first nine months of this year. Agfa says that its managing decline in its medical film business whilst seeing some increases in its direct radiography solutions. It blames most of the issues on falling volumes and manufacturing inefficiencies.

Overall, the Agfa-Gevaert Group posted revenues of €277 million, with an adjusted EBITDA of €15 million, which is down on last year’s Q3 figures of €280 million revenue and €17 million EBITDA. Nonetheless, the final net figure was a loss of €13 million, which was an improvement on the €15 million loss from Q3 2023. Furthermore, the net result was the first nine months of this year was a loss of €29 million, which is a distinct improvement on the previous year’s loss of €96 million. Elsewhere, the net financial debt rose from €99 million in Q2 to €118 million by the end of Q3, and the group generated a €6 million loss in its free cash flow.
Pascal Juéry, President and CEO of the Agfa-Gevaert Group, commented: “I am pleased with the evolution of our growth engines. The Digital Print & Chemicals division reported double-digit top line growth and doubled its adjusted EBITDA, driven by Digital Print Solutions and Green Hydrogen Solutions. HealthCare IT’s order intake is growing strongly, powered by our cloud solutions attracting net new customers. Our first go-live of our cloud-based Enterprise Imaging platform was a full success, demonstrating the robustness of our solutions. Having a reference site will add to the momentum we are seeing for this technology.”
However, Agfa is still to agree a final price for the Offset Solutions division that it sold to the Aurelius Group in April 2023, with the matter now to be determined by an independent expert.
Agfa has also announced a cost cutting plan for its film related activities, which will lead to up to 530 redundancies but is expected to save €50 million by the end of 2027, starting in 2025.
Juéry added: “Finally, the plan to adjust the cost base of our traditional film activities to the reality in the market is on track. We expect that this self-funding program will allow us to reduce the cost base of these activities by 50 million euro by the end of 2027. The first savings will start to materialize in the second half of 2025.”
You can find further details from agfa.com.


Leave a Reply